Analyzing Theratechnologies (NASDAQ:THTX) & RedHill Biopharma (NASDAQ:RDHL)

Theratechnologies (NASDAQ:THTX) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings.

Earnings & Valuation

This table compares Theratechnologies and RedHill Biopharma’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theratechnologies	$81.76 million	0.73	-$23.96 million	($0.61)	-2.13
RedHill Biopharma	$6.53 million	1.67	$23.92 million	N/A	N/A

RedHill Biopharma has lower revenue, but higher earnings than Theratechnologies.

Insider and Institutional Ownership

7.2% of RedHill Biopharma shares are owned by institutional investors. 6.8% of RedHill Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Theratechnologies and RedHill Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theratechnologies	-23.04%	N/A	-26.15%
RedHill Biopharma	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for Theratechnologies and RedHill Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theratechnologies	0	0	1	0	3.00
RedHill Biopharma	0	0	0	0	N/A

Risk and Volatility

Theratechnologies has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Comparatively, RedHill Biopharma has a beta of 3.56, meaning that its share price is 256% more volatile than the S&P 500.

Summary

RedHill Biopharma beats Theratechnologies on 7 of the 9 factors compared between the two stocks.

About Theratechnologies

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.